Somatostatin plus Ulinastatin and/or Gabexate for Severe Acute Pancreatitis

doi:10.12114/j.issn.1007-9572.2018.34.016

Abstract

Abstract: Objective　To evaluate the effectiveness of Somatostatin（SM） plus Ulinastatin（US） or/and Gabexate（GB） for the treatment of severe acute pancreatitis（SAP）.Methods　A total of 266 consecutive patients with SAP who received treatment during July 2008 to January 2018 were enrolled.Based on table of random number，they were divided into 4 groups，receiving SM，SM plus GB，SM plus US，SM plus US and GB，respectively.Clinical parameters including abdominal pain and distention relief time，normal autonomous respiration recovery time，normal heart rate recovery time，normal serum amylase recovery time，blood glucose recovery time，white blood count（WBC），C reaction protein（CRP），blood urea nitrogen（BUN），serum creatinine（Scr），hospitalization costs，length of stay（LOS） and cure rate，incidences of adverse reaction and mortality were analyzed.Results　Both SM plus GB，and SM plus US groups needed less time for abdominal pain and distention relief，recovery of normal autonomous respiration，normal heart rate，normal serum amylase and normal blood glucose，and showed decreased WBC and CRP compared with SM group（P<0.05），as did SM plus US and GB group when compared with SM plus GB group or SM plus US group（P<0.05）.SM plus GB，and SM plus US and GB groups also showed decreased BUN in comparison to SM group，as did SM plus US and GB group when compared with SM plus US group（P<0.05）. Compared with SM group，both SM plus US group and SM plus US and GB group had higher hospitalization costs（P<0.05）. SM plus US and GB group had higher hospitalization costs than SM plus US group（P<0.05）. Furthermore，SM plus GB group and SM plus US group had shorter LOS compared with SM　group（P<0.05）. In comparison with SM plus GB group or SM plus US group，the LOS was shorter in the SM plus US and GB group（P<0.05）.　Significant differences in the cure rate，incidence of adverse reactions and mortality were detected by the overall comparison among the four groups（P<0.05）. However，pairwise comparisons did not find obvious differences in the cure rate，incidence of adverse reactions and mortality（P>0.008 3）. Conclusion　SM is effective for SAP.Moreover，the effectiveness will be better if it is used in combination with US or GB，and far better if used in combination with both the two.

Key words: Pancreatitis, Somatostatin, Gabexate, Ulinastatin, Treatment outcome

摘要： 目的　探讨生长抑素（SM）联合乌司他丁（US）和/或加贝酯（GB）治疗重症急性胰腺炎（SAP）的效果。方法　选择2008年7月—2018年1月收治的266例SAP患者，按随机数字表法分为SM、SM+GB、SM+US、SM+US+GB组。比较4组腹胀消失时间、腹痛消失时间、呼吸恢复正常时间、心率恢复正常时间、血清淀粉酶恢复正常时间、血糖恢复正常时间、白细胞计数（WBC）、C反应蛋白（CRP）、血尿素氮（BUN）、血肌酐（Scr）、住院费用、住院时间、治愈率、不良反应发生率及病死率。结果　SM+GB组及SM+US组的腹胀消失时间、腹痛消失时间、呼吸恢复正常时间、心率恢复正常时间、血清淀粉酶恢复正常时间、血糖恢复正常时间、WBC和CRP均低于SM组，差异有统计学意义（P<0.05）；SM+US+GB组的上述参数均低于SM+GB组或SM+US组，差异有统计学意义（P<0.05）。SM+US组及SM+US+GB组的BUN低于SM组，SM+US+GB组低于SM+US组，差异有统计学意义（P<0.05）。SM+US组及SM+US+GB组的住院费用高于SM组，SM+US+GB组高于SM+US组，差异有统计学意义（P<0.05）；SM+GB组及SM+US组的住院时间短于SM组，SM+US+GB组的住院时间短于SM+GB组或SM+US组，差异有统计学意义（P<0.05）；4组治愈率、不良反应发生率、病死率比较，差异有统计学意义（P<0.05），但两两比较，差异无统计学意义（P>0.008 3）。结论　SM能有效治疗SAP，联用US或GB均能提高临床疗效，联用US和GB效果更佳。

关键词: 胰腺炎, 生长抑素, 加贝酯, 乌司他丁, 治疗结果

WANG Guiliang,QIU Ping,XU Linfang, et al. Somatostatin plus Ulinastatin and/or Gabexate for Severe Acute Pancreatitis　[J]. Chinese General Practice, 2018, 21(34): 4241-4245. DOI: 10.12114/j.issn.1007-9572.2018.34.016.
王桂良,邱萍,徐林芳等. 生长抑素联合乌司他丁和/或加贝酯治疗重症急性胰腺炎的临床疗效研究[J]. 中国全科医学, 2018, 21(34): 4241-4245. DOI: 10.12114/j.issn.1007-9572.2018.34.016.

References

［1］汤华，桑卫东.重症急性胰腺炎微创治疗研究进展［J］.安徽医学，2018，46（3）：367-369.DOI：10.3969/j.issn.1000-0399.2018.03.037.
TANG H，SANG W D.Advances in minimally invasive treatment of severe acute pancreatitis［J］.Anhui Medical Journal，2018，46（3）：367-369.DOI：10.3969/j.issn.1000-0399.2018.03.037.
［2］PORTELLI M，JONES C D.Severe acute pancreatitis：pathogenesis，diagnosis and surgical management［J］.Hepatobiliary Pancreat Dis Int，2017，16（2）：155-159.
［3］SHAH A P，MOURAD M M，BRAMHALL S R.Acute pancreatitis：current perspectives on diagnosis and management［J］.J Inflamm Res，2018，11：77-85.DOI：10.2147/JIR.S135751.
［4］SETA T，NOGUCHI Y，SHIKATA S，et al.Treatment of acute pancreatitis with protease inhibitors administered through intravenous infusion：an updated systematic review and meta-analysis［J］.BMC Gastroenterol，2014，14：102.DOI：10.1186/1471-230X-14-102.
［5］WANG G，WEN J，WILBUR R R，et al.The effect of Somatostatin，Ulinastatin and Salvia Miltiorrhiza on severe acute pancreatitis treatment［J］.Am J Med Sci，2013，346（5）：371-376.DOI：10.1097/MAJ.
［6］KIM S C，YANG H R.Clinical efficacy of Gabexate Mesilate for acute pancreatitis in children［J］.Eur J Pediatr，2013，172（11）：1483-1490.DOI：10.1007/s00431-013-2068-6.
［7］ABRAHAM P，RODRIQUES J，MOULICK N，et al.Efficacy and safety of intravenous Ulinastatin versus placebo along with standard supportive care in subjects with mild or severe acute pancreatitis［J］.J Assoc Physicians India，2013，61（8）：535-538.
［8］中华医学会消化病学分会胰腺疾病学组.中国急性胰腺炎诊治指南（草案）［J］.中华消化杂志，2004，24（3）：190-192.
Pancreatology Group，Chinese Society of Gastroenterology.The Chinese treatment of acute pancreatitis guide（draft）［J］.Chin J Dig，2004，24（3）：190-192.
［9］BOLLEN T L，VAN SANTVOORT H C，BESSELINK M G，et al.The atlanta classification of acute pancreatitis revisited［J］.Br J Surg，2008，95（1）：6-21.
［10］TALUKDAR R，SWAROOP VEGE S.Early management of severe acute pancreatitis［J］.Curr Gastroenterol Rep，2011，13（2）：123-130.DOI：10.1007/s11894-010-0174-4.
［11］HARPER S J，CHESLYN-CURTIS S.Acute pancreatitis［J］.Ann Clin Biochem，2011，48（Pt 1）：23-37.DOI：10.1258/acb.2010.010196.
［12］ZEREM E.Treatment of severe acute pancreatitis and its complications［J］.World J Gastroenterol，2014，20（38）：13879-13892.DOI：10.3748/wjg.v20.i38.13879.
［13］SCHEPERS N J，BESSELINK M G，VAN SANTVOORT H C，et al.Early management of acute pancreatitis［J］.Best Pract Res Clin Gastroenterol，2013，27（5）：727-743.DOI：10.1016/j.bpg.2013.08.007.
［14］JIANG W，YU X，SUN T，et al.Adjunctive Ulinastatin in Sepsis Treatment in China（ADJUST study）：study protocol for a randomized controlled trial［J］.Trials，2018，19（1）：133.DOI：10.1186/s13063-018-2513-y.
［15］INO Y，ARITA Y，AKASHI T，et al.Continuous regional arterial infusion therapy with Gabexate Mesilate for severe acute pancreatitis［J］.World J Gastroenterol，2008，14（41）：6382-6387.
［16］GAO H J，SONG Q，LYU F Q，et al.A novel thermosensitive in-situ gel of Gabexate Mesilate for treatment of traumatic pancreatitis：an experimental study［J］.J Huazhong Univ Sci Technolog Med Sci，2015，35（5）：707-711.DOI：10.1007/s11596-015-1494-2.
［17］HOU J，ZHU M W，HE X W，et al.Effect of hyperbaric oxygen and Ulinastatin on plasma endotoxin，soluble CD14，endotoxin-neutralizing capacity and cytokines in acute necrotizing pancreatitis［J］.Can J Surg，2010，53（4）：241-245.
［18］KARNAD D R，BHADADE R，VERMA P K，et al.Intravenous administration of Ulinastatin（human urinary trypsin inhibitor） in severe sepsis：a multicenter randomized controlled study［J］.Intensive Care Med，2014，40（6）：830-838.DOI：10.1007/s00134-014-3278-8.
［19］ANDRIULLI A，LEANDRO G，CLEMENTE R，et al.Meta-analysis of Somatostatin，Octreotide and Gabexate Mesilate in the therapy of acute pancreatitis［J］.Aliment Pharmacol Ther，1998，12（3）：237-245.
［20］LAGOO J Y，D'SOUZA M C，KARTHA A，et al.Role of Ulinastatin，a trypsin inhibitor，in severe acute pancreatitis in critical care setting：a retrospective analysis［J］.J Crit Care，2018，45：27-32.DOI：10.1016/j.jcrc.2018.01.021.
［21］FENG C，SU X，CHEN L I，et al.Ulinastatin enhances the therapeutic effect of intraperitoneal lavage on severe acute pancreatitis in rats［J］.Exp Ther Med，2015，9（5）：1651-1655.
［22］YASUNAGA H，HORIGUCHI H，HASHIMOTO H，et al.Effect and cost of treatment for acute pancreatitis with or without Gabexate Mesilate：a propensity score analysis using a nationwide administrative database［J］.Pancreas，2013，42：260-264.DOI：10.1097/MPA.0b013e31826495a0.

[1]	YAO Yuzhong, MA Xiaojun, SONG Huan, ZHONG Yu. The Management Effect of Diabetes "1358 model" on Community Diabetes Patients Based on "Precision Management Combining General Care and Specialty Care" [J]. Chinese General Practice, 2023, 26(34): 4308-4314.
[2]	LI Qian, ZHANG Yunshu, YAN Baoping, WANG Jian, MA Yanjuan, WANG Yuan, QIN Yingjie, NA Long, REN Zhiyong, SUN Junwei, DENG Huaili, MA Hongjun, QU Xuehui, ZHOU Nan, SI Tianmei. Efficacy and Safety of Risperidone Microspheres for Injection (Ⅱ) in the Treatment of Patients with Acute Schizophrenia [J]. Chinese General Practice, 2023, 26(32): 4007-4012.
[3]	YAO Junjie, SHANG Qiangqiang, WANG Yufeng, LI Jiahui, LIU Chang, PANG Tingting. Wearable Inertial Sensors-based Efficacy Evaluation of Comprehensive Traditional Chinese Medicine Therapy for Lumbar Disc Herniation Due to Qi-stagnation and Blood-stasis [J]. Chinese General Practice, 2023, 26(27): 3450-3455.
[4]	LIU Minghao, WANG Pan, GAO Lijian, XU Shuqing, WANG Huanhuan, ZHAO Guangxian, CHEN Jue, QIAO Shubin, XU Bo, YUAN Jinqing. Feasibility, Safety and Timing of Secondary Percutaneous Coronary Intervention via Distal Transradial Artery Approach [J]. Chinese General Practice, 2023, 26(27): 3366-3372.
[5]	LU Bin, XIANG Chong, YUAN Xuesong, CAI Gaojun, WEI Wenfeng, YAN Yongmin. Effectiveness, Safety and Satisfaction of Distal Transradial Artery Approach in Cerebral Angiography [J]. Chinese General Practice, 2023, 26(27): 3378-3382.
[6]	Expert group of expert consensus on the application of ulinastatin in common clinical critical illness. Expert Consensus on the Application of Ulinastatin in Common Clinical Critical Illness [J]. Chinese General Practice, 2023, 26(26): 3207-3219.
[7]	HU Xiaofei, ZHAO Ping, CAO Tinghua, PENG Lanlan. Study on the Predictive Value of Abdominal Fat Content and Distribution in the Acute Pancreatitis and Its Severity [J]. Chinese General Practice, 2023, 26(21): 2614-2619.
[8]	GAO Yang, WANG Yunxia, GAO Chuanyu. Familial Hypercholesterolemia in 45-year-old and Younger Patients with Acute Coronary Syndrome: Clinical Characteristics and Influencing Factors of Blood Lipid Control Effect [J]. Chinese General Practice, 2023, 26(18): 2232-2237.
[9]	SU Afang, ZHU Guoling, ZHANG Yunshui, CHEN Shuohua, ZHAO Xiujuan, YANG Wenhao, WANG Yinjie, WANG Fengfei, XIN Yingying, WU Shouling, ZHANG Jie, JIANG Xiaozhong. Association between Baseline Fasting Plasma Glucose Levels and Risk of Acute Pancreatitis in Non-obese Population: a Prospective Cohort Study [J]. Chinese General Practice, 2023, 26(18): 2203-2208.
[10]	YANG Bei, HAN Lin, WANG Yin, CHENG Kangyao. Effectiveness of Continuous Subcutaneous Insulin Injection in Type 2 Diabetes in Older Adults: a Meta-analysis and Trial Sequential Analysis [J]. Chinese General Practice, 2023, 26(15): 1892-1901.
[11]	LIU Chuanfen, LI Zheng, WU Manyan, CUI Yuxia, SONG Jing, ZHANG Chunying, CHEN Hong. Analysis of Serum Lipid Level and Drug Use in Patients with Acute Myocardial Infarction [J]. Chinese General Practice, 2023, 26(11): 1325-1329.
[12]	HUANG Xiangping, WU Ling, TAN Chaochao. Serum Metabolomic Study on the Difference between Mild and Severe Acute Pancreatitis Based on Liquid Chromatography-tandem Mass Spectrometry [J]. Chinese General Practice, 2023, 26(09): 1118-1124.
[13]	FEI Jingwen, LIN Huize, ZHANG Pingping, LIU Lanping, WANG Xiang, SHEN Jianghong, ZHU Kexin, YANG Tao, YU Jinna. Motion Style Acupuncture Can Effectively Improve the Effectiveness of Acute Nonspecific Low Back Pain: a Meta-analysis [J]. Chinese General Practice, 2023, 26(09): 1044-1052.
[14]	GUAN Ningxiao, YAO Zhuoya, LI Ye, LIU Ziwei, LIU Fangli. Non-invasive Brain Stimulation Techniques Can Effectively Relieve Post-stroke Fatigue: a Meta-analysis [J]. Chinese General Practice, 2023, 26(08): 1008-1014.
[15]	HE Xiaoli, LIANG Shuheng, LI Miaoxia, KONG Jinliang, SHAN Qingwen. Hereditary Pancreatitis in Children: Report of One Case with Pedigree Analysis and Literature Review [J]. Chinese General Practice, 2023, 26(05): 641-646.